MPA Revisited: A Phase II Study of Anti-Metastatic Anti-Angiogenic Therapy in Postmenopausal Patients with Hormone Receptor Negative Breast Cancer
K
Kathy Miller, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Overview
No Description Available
Description
No Description Available
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Breast Cancer
-
Age: Between 55 Years - 100 Years
-
Gender: Female
Updated on
02 May 2024.
Study ID: 1011004167 (0607-18)